World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
105
Citations
47630
World Ranking
6707
National Ranking
3541

Vibeke Strand publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Vibeke Strand sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 704 publications — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Vibeke Strand D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Vibeke Strand sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 105 D-Index — 67th percentile

67% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Vibeke Strand is affiliated with Stanford University in the United States and has contributed extensively to the field of medicine, with particular focus on rheumatology. Their research spans a broad range of subfields including immunology, hematology, genetics, and economics and econometrics.

The main topics of Vibeke Strand's work center on rheumatoid arthritis research and therapies, spondyloarthritis studies and treatments, psoriasis treatment and pathogenesis, autoimmune and inflammatory disorders research, systemic lupus erythematosus research, chronic lymphocytic leukemia research, and health systems, economic evaluations, and quality of life.

Their recent publications demonstrate involvement in various significant studies:

  • Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial, 2020, Arthritis & Rheumatology
  • Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations, 2020, Pain
  • The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems, 2021, Seminars in Arthritis and Rheumatism
  • The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases, 2020, Journal of Allergy and Clinical Immunology
  • Immunogenicity of biologic agents in rheumatology, 2020, Nature Reviews Rheumatology

Their frequent coauthors include:

  • Philip J. Mease
  • Robin Christensen
  • Joseph F. Merola
  • Dafna D. Gladman
  • Niti Goel

Most of Vibeke Strand's work has been published in notable venues such as:

  • Annals of the Rheumatic Diseases
  • Seminars in Arthritis and Rheumatism
  • The Journal of Rheumatology
  • Lara D. Veeken
  • The Lancet Rheumatology

Best Publications

  • American college of rheumatology preliminary definition of improvement in rheumatoid arthritis

    David T. Felson;David T. Felson;Jennifer J. Anderson;Jennifer J. Anderson;Maarten Boers;Claire Bombardier;Claire Bombardier

  • American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

    David T. Felson;David T. Felson;Josef S. Smolen;George Wells;Bi Zhang

  • OMERACT-OARSI Initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited.

    T. Pham;D. van der Heijde;R. D. Altman;J. J. Anderson

  • Recommendations for a core set of outcome measures for future Phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III

    Nicholas Bellamy;John Kirwan;Maarten Boers;Peter Brooks

  • Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate

    Vibeke Strand;Stanley Cohen;Michael Schiff;Arthur Weaver

  • Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0

    Maarten Boers;John R. Kirwan;George Wells;Dorcas Beaton

  • Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

    Edward Keystone;Désireé Van Der Heijde;David Mason;Robert Landewé

  • Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

    Daniel E Furst;Michael H Schiff;Roy M Fleischmann;Vibeke Strand

  • OMERACT: An international initiative to improve outcome measurement in rheumatology

    Peter Tugwell;Maarten Boers;Peter Brooks;Lee Simon

  • Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.

    D. Aletaha;R.B. Landewe;T. Karonitsch;J. Bathon

  • Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

    J Smolen;R B Landewé;P Mease;J Brzezicki

  • Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study.

    Clifton O. Bingham;J. Chris Buckland-Wright;Patrick Garnero;Stanley B. Cohen

  • Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

    Joel M. Kremer;Mark C. Genovese;Grant W. Cannon;Jacques R. Caldwell

  • Novel Evidence-Based Systemic Lupus Erythematosus Responder Index

    Richard A. Furie;Michelle A. Petri;Daniel J. Wallace;Ellen M. Ginzler

  • Minimal clinically important differences: review of methods.

    George Wells;Dorcas Beaton;Beverley Shea;Maarten Boers

  • Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study

    R Fleischmann;J Vencovsky;R F van Vollenhoven;D Borenstein

  • Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate

    Stanley Cohen;Grant W. Cannon;Michael Schiff;Arthur Weaver

  • Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study.

    Vlastimir Mladenovic;Zlatko Domljan;Blaz Rozman;Ivo Jajic

  • Mechanism of action for leflunomide in rheumatoid arthritis.

    Robert I. Fox;Matthias L. Herrmann;Costakis G. Frangou;Geoffrey M. Wahl

  • Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis

    John T. Sharp;Vibeke Strand;Hoi Leung;Frank Hurley

Frequent Co-Authors

Philip J. Mease
Philip J. Mease University of Washington
Peter Tugwell
Peter Tugwell University of Ottawa
Jasvinder A. Singh
Jasvinder A. Singh Veterans Health Administration
Maarten Boers
Maarten Boers Vrije Universiteit Amsterdam
Dafna D. Gladman
Dafna D. Gladman Toronto Western Hospital
Daniel E. Furst
Daniel E. Furst University of California, Los Angeles
Peter Brooks
Peter Brooks University of Melbourne
Robin Christensen
Robin Christensen University of Southern Denmark
Désirée van der Heijde
Désirée van der Heijde Leiden University Medical Center
Roy Fleischmann
Roy Fleischmann The University of Texas Southwestern Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a medical career in the USA, a range of online nursing programs can help you reach your goals faster and with more flexibility. For registered nurses seeking to advance their qualifications, exploring online rn to bsn programs without clinical requirements is a practical option. These programs can be ideal for those balancing work and study, as they remove the need for on-site clinical rotations.

Advancement in nursing often leads to doctoral degrees. If you want to fast-track your education, consider enrolling in one of the quickest dnp program options available online. For those seeking flexibility and less intensive entry requirements, many dnp programs can be completed remotely and cater to different professional backgrounds.

If you are beginning your nursing journey, online lpn program pathways can help you enter the healthcare workforce quickly. These programs are designed for those eager to start their medical careers with a shorter, focused curriculum, offering both speed and convenience.

Best Scientists Citing Vibeke Strand

Trending Scientists

Recently Published Articles